子宫浆液性癌与BRCA1/2相关癌症综合征的关联:一项Meta分析与病例报告
该系统评价与Meta分析检索截至2016年7月的文献,纳入10项研究共345例子宫浆液性癌(USC)患者,发现德系犹太人USC患者的胚系BRCA1/2致病突变汇总比值比为5.4(95%CI 2.2-13.1),高于德系犹太人一般人群;一例携带胚系BRCA1致病突变的USC病例肿瘤DNA中检出该突变,并显示野生型等位基因杂合性缺失及同源重组缺陷。作者认为USC可能是BRCA1/2相关遗传性乳腺癌卵巢癌综合征被忽视的组成部分,对USC患者应考虑胚系BRCA1/2突变筛查,尤其是一级亲属有乳腺癌和/或卵巢癌家族史者。
要点
- 德系犹太人USC患者胚系BRCA1/2致病突变汇总OR为5.4(95%CI 2.2-13.1),高于一般德系犹太人人群。
- 一例USC病例肿瘤DNA中检出已知胚系BRCA1致病突变,并见野生型等位基因杂合性缺失及同源重组缺陷。
- 作者认为对USC患者应考虑胚系BRCA1/2突变筛查,尤其一级亲属有乳腺癌和/或卵巢癌家族史者。
核心结论
- 本研究提示USC可能是BRCA1/2相关遗传性乳腺癌卵巢癌综合征中被忽视的组成部分。
- 作者认为对诊断为USC的患者应考虑胚系BRCA1/2致病突变筛查,尤其是一级亲属有乳腺癌和/或卵巢癌家族史者。
研究设计与样本
- 检索PubMed、EMBASE和Web of Science(2016年7月)中评估USC与胚系BRCA1/2致病突变关联的文章。
- 采用随机效应logistic模型进行汇总分析与比较,按族裔(德系犹太人与非德系犹太人)分层。
- 检索共获得1893条引用,最终纳入10项研究,描述345例USC患者。
- 对一例携带遗传性BRCA1致病突变的USC病例的肿瘤组织分析BRCA1位点杂合性缺失,并进行同源重组功能分析。
主要发现
- 德系犹太人USC患者携带胚系BRCA1/2致病突变的汇总比值比为5.4(95%CI 2.2-13.1),高于德系犹太人一般人群。
- 在一例USC患者的肿瘤DNA中鉴定出已知的胚系BRCA1致病突变。
- 该病例显示野生型等位基因杂合性缺失及同源重组缺陷。
临床怎么用
- 作者认为对诊断为USC的患者应考虑胚系BRCA1/2致病突变筛查,尤其是一级亲属有乳腺癌和/或卵巢癌家族史者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine serous carcinoma (USC) shows greater morphological, clinical and molecular similarities to high-grade ovarian tubal serous carcinoma than to other types of endometrial cancer. As high-grade ovarian tubal serous carcinoma is known to be associated with BRCA1/2 pathogenic germline mutations (PMs), we aimed to explore whether USC is also a constituent of hereditary breast and ovarian cancer syndrome. METHODS: Pubmed, EMBASE and Web of Science were searched in July 2016 for articles assessing the association between USC and germline BRCA1/2-PMs. Pooled analysis and comparisons were performed using a random effects logistic model, stratifying for ethnicity (Ashkenazi versus non-Ashkenazi). In addition, tumour tissue from an USC case with a hereditary BRCA1-PM was analysed for loss of heterozygosity at the BRCA1 locus and was functionally analysed for homologous recombination proficiency. RESULTS: The search yielded 1893 citations, 10 studies were included describing 345 USC patients. For Ashkenazi Jews, the pooled odds ratio of having a germline BRCA1/2-PM was increased in USC patients compared with the general Ashkenazi population: odds ratio 5.4 (95%confidence interval: 2.2-13.1). In the patient with USC, we identified the known germline BRCA1-PM in the tumour DNA. Furthermore, we showed both loss of heterozygosity of the wild-type allele and a deficiency of homologous recombination. CONCLUSION: This study suggests that USC may be an overlooked component of BRCA1/2-associated hereditary breast and ovarian cancer syndrome. Screening for germline BRCA1/2-PMs should be considered in patients diagnosed with USC, especially in cases with a positive first-degree family history for breast and/or ovarian cancer.
引用
- de Jonge MM, Mooyaart AL, Vreeswijk MP, et al. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. Eur J Cancer. 2016. PMID: 28049106. doi:10.1016/j.ejca.2016.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。